A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

ClinicalTrials.gov ID: NCT07592689

Public ClinicalTrials.gov record NCT07592689. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 19, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Ascend

Study identification

NCT ID: NCT07592689
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Enrollment: 165 participants

Conditions and interventions

Conditions

Major Depressive Disorder

Interventions

DT120 Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 74 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 9, 2026
Primary completion: Aug 31, 2027
Completion: May 31, 2028
Last update posted: May 17, 2026

2026 – 2028

United States locations

U.S. sites: 18
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
Lighthouse Psychiatry	Gilbert	Arizona	85234	Not yet recruiting
Preferred Research Partners, Inc.	Little Rock	Arkansas	72211	Recruiting
UCSF Department of Neurology	San Francisco	California	94158	Not yet recruiting
Psychedelic Science Institute	Santa Monica	California	90404	Not yet recruiting
Mountain View Clinical Research, Inc	Denver	Colorado	80209	Recruiting
Charter Research	Orlando	Florida	32803	Not yet recruiting
CenExel Atlanta	Atlanta	Georgia	30331	Recruiting
CenExel Decatur	Decatur	Georgia	30030	Recruiting
CenExel Savannah	Savannah	Georgia	31405	Recruiting
Uptown Research Institute	Chicago	Illinois	60640	Recruiting
Adams Clinical Boston	Boston	Massachusetts	02116	Recruiting
Adams Clinical Harlem	New York	New York	10029	Recruiting
Cleveland Clinic	Cleveland	Ohio	44113	Not yet recruiting
Adams Clinical Philadelphia	Philadelphia	Pennsylvania	19104	Recruiting
Coastal Carolina Research	North Charleston	South Carolina	29405	Recruiting
Cedar Clinical Research	Draper	Utah	84020	Recruiting
Inner Space Research	Orem	Utah	84058	Recruiting
VA Portland Healthcare System	Vancouver	Washington	98661	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07592689, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 17, 2026 · Synced May 19, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07592689 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →